Compare Gilead Sciences, Inc. (GILD) vs Direxion Daily Semiconductor Bull 3X Shares (SOXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Direxion Daily Semiconductor Bull 3X Shares — how do they compare? Gilead Sciences, Inc. trades at $134.39 (market cap $163.51B), while Direxion Daily Semiconductor Bull 3X Shares trades at $141.32. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while Direxion Daily Semiconductor Bull 3X Shares pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, Direxion Daily Semiconductor Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| GILD | SOXL | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $155.80 | $300.77 |
52-Week Low | $108.22 | $23.99 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SOXL, the Direxion Daily Semiconductor Bull 3X Shares ETF, is trading at $145.35, down 17.72% in the past 24 hours amid a broader semiconductor selloff. Technical indicators show a bearish trend with support at $125 and resistance at $178, while RSI levels near 35 suggest potential oversold conditions. Recent news highlights volatility driven by SK Hynix's U.S. listing and increased competition in memory chips, impacting leveraged ETF performance.
The outlook for SOXL remains highly volatile due to its 3x leverage on semiconductor stocks, amplifying both gains and losses. Investment opportunity exists if semiconductor sentiment rebounds, but risks include decay from choppy markets and sector-specific pressures. Caution is warranted given the bearish technical signals and recent institutional selling.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Direxion Daily Semiconductor Bull 3X Shares
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →
